Companies
(73)
AAC Clyde Space
ALM Equity
Alzinova
Arion Bank
Arlandastad Group
Ascelia Pharma
Bactiguard
Bergman & Beving
Besqab
BioPorto
Björn Borg
Bokusgruppen
Bonava
BTS Group
Byggmästaren
CAG Group
Calviks
Carasent
CDON
Clavister
Clemondo Group
eEducation Albert
Elanders
Elicera Therapeutics
Eolus
Ependion
EQL Pharma
Faron Pharmaceuticals
FluoGuide
Gentoo Media
GiG Software
HAKI Safety
HANZA
Iconovo
Idun Industrier
InfraCom
Initiator Pharma
Intervacc
ITAB Group
Kebni
Lifecare ASA
Lindex Group
Logistri
Lumi Education Group
Lytix Biopharma
Medivir
Mentice
Micro Systemation
MilDef Group
Net Insight
Nordic LEVEL Group
Orexo
Ortoma
OssDsign
Paxman
Pierce
PowerCell
Pricer
Qualisys
Relais Group
SaltX
Scanfil
Sensys Gatso Group
Sleep Cycle
Solar Foods
Spago Nanomedical
Svedbergs Group
Taaleri
Terranor
Vertiseit
Vivesto
W5 Solutions
Waystream
Sweden
Healthcare
Elicera Therapeutics is a Swedish clinical-stage biotechnology company developing next-generation immuno-oncology treatments, focusing on enhanced CAR T-cell therapies and oncolytic viruses. The company’s proprietary and commercially available iTANK platform is an engineered ‘arming’ technology designed to boost the efficacy of CAR T therapies and oncolytic viruses, particularly in solid tumours. iTANK is already integrated into three of Elicera’s lead candidates (ELC-301, ELC-401 and ELC-201) and is also available for out-licensing to other CAR T/TCR T developers.
Key industry drivers
Increasing incidence and prevalence of cancer
Ever growing demand for more effective treatments in difficult-to-treat population
Industry outlook
The market for oncology drugs is expected to grow at double-digit rate over the coming five years (IQVIA)
Larger pharmaceutical companies face patent cliffs, which we believe will continue to drive interest in in-licensing
Key peers
BioInvent, Faron Pharmaceuticals
Name
Capital
Votes
Avanza
10.1 %
10.1 %
Di Yu
5.2 %
5.2 %
Magnus Essand
5.1 %
5.1 %
Jamal El-Mosleh
4.1 %
4.1 %
Nordnet
3.7 %
3.7 %
Other owners
71.7 %
71.7 %
About DNB Carnegie Access
DNB Carnegie Access aim is to connect listed companies with the capital markets. Through top ranked public equity research and broad distribution via written reports, seminars, video, and podcasts, we increase visibility and investor understanding for small- and medium-sized companies, both among institutional and private investors.
Along with corporate finance, market making and certified advisory we provide a complete product offering to our clients.
Private Banking
Tailored wealth management. Your financial future, personalized.
Montrose
A digital investment platform designed for passionate investors.
DNB Carnegie
Leading Nordic investment bank and wealth management.
© Copyright DNB Carnegie Investment Bank AB